Axsome Therapeutics, Inc.
https://axsome.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Axsome Therapeutics, Inc.
Delay Looms For Axsome Therapeutics’ Entry Into Major Depressive Disorder Market With Lead Product
Axsome Therapeutics’ lead candidate, AXS-05, was nearing the US market for major depressive disorder, but the US company is trying to find out more about deficiencies identified by US regulators; the biotech has also reported positive Phase II results in treatment-resistant depression.
T-knife Taps Into Investor Interest in T-Cell Receptor Therapies
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s
The pending US FDA decision on Biogen’s drug overshadows progress in Alzheimer’s diagnosis, symptomatic treatments and the need to keep studying anti-tau therapies after Roche’s setback.
Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Pharmaceuticals